Market Minds Advisory
Castration-Resistant Prostate Cancer (CRPC) Treatment Market

Castration-Resistant Prostate Cancer (CRPC) Treatment Market: The Radioligand Therapy Inflection

Radioligand therapy is pulling castration-resistant prostate cancer treatment beyond its androgen receptor inhibitor foundation, forcing oncology majors to build nuclear medicine manufacturing capability or cede the fastest-growing treatment line to specialized radiopharmaceutical developers.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$16.8BMarket Size 2025
2036 FORECAST VALUE$40.8BBase Case , 2026 to 2036
CAGR 2026 TO 20368.4 %Bull 9.7% / Bear 7.1%
INCREMENTAL OPPORTUNITY$22.6BNet 10- year value creation
EXPANSION MULTIPLE2.24x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Androgen receptor pathway inhibitors remain the CRPC treatment backbone across most diagnosed patients today, but radioligand therapy's rapid commercial uptake since 2022 is reshaping which developers can realistically compete for the growing, higher-value later-line treatment segment across major oncology markets worldwide, nationally and internationally, in the years just ahead now.
Radioligand, or targeted radionuclide, therapies are the fastest growing category as PSMA-targeted radiopharmaceuticals demonstrate meaningful survival benefit in later treatment lines for patients who have exhausted standard options, while North America commands the largest regional share on the strength of concentrated specialty oncology reimbursement and considerably higher per-patient drug pricing than any other region, a gap wide enough that it shapes global developer commercial strategy more than population size alone would ever suggest.
A handful of oncology majors dominate branded androgen receptor inhibitor and radioligand therapy distribution through direct specialty pharmacy and infusion center relationships nationwide, while smaller radiopharmaceutical developers compete for licensing deals once early trial data reads out favorably across multiple programs. Nuclear medicine manufacturing capacity and isotope supply chain access are increasingly determining which developers can scale radioligand therapy commercially at all.
Market Definition
CRPC treatment covers pharmacological therapies used to manage castration-resistant prostate cancer, including androgen receptor pathway inhibitors, PARP inhibitors, radioligand therapies, chemotherapy, immunotherapy, and bone-targeted agents administered after disease progression despite androgen deprivation. It excludes initial hormone-sensitive prostate cancer treatment, surgical intervention, and radiation therapy delivered outside a radioligand or radiopharmaceutical mechanism.
Base Year Value
$16.8B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.4% base case. Bull 9.7%. Bear 7.1%.
Fastest Growth Segment
Radioligand (Targeted Radionuclide) Therapies: 17.6% CAGR
Fastest Growth Country
United States: 9.4% CAGR
Fastest Growth Region
South Asia and Pacific: 10.4% CAGR
Largest Region
North America: 36% of 2025 global value
Market Leaders
Astellas Pharma Inc, Pfizer Inc, Johnson & Johnson (Janssen), Novartis AG, Bayer AG. Source: MMA Analysis based on company annual reports and investor filings.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Castration-Resistant Prostate Cancer (CRPC) Treatment Market Forecast Scenarios

castration-resistant-prostate-cancer-crpc-treatmen-size-forecast-scenario-1787298062445
CRPC treatment demand grew steadily from 2020 as androgen receptor pathway inhibitors expanded into earlier treatment lines and diagnosis rates recovered from pandemic era screening disruption. Radioligand therapy commercial launch from 2022 onward added an entirely new, high value treatment line to the market. The market grew at a historical rate of roughly 7.6% annually across this period.
The base case rests on three mechanisms: androgen receptor pathway inhibitors continuing to expand into earlier disease stages as trial data supports broader regulatory indications across multiple patient populations and geographies, radioligand therapy adoption scaling as nuclear medicine infrastructure and isotope supply chains mature across major oncology markets worldwide, and rising diagnosed prevalence tied to aging populations sustaining demand across every treatment line simultaneously and consistently over the full forecast period.
The bull case rests on faster than expected radioligand therapy manufacturing capacity expansion resolving the isotope supply constraints that have limited broader patient access to date across most oncology markets. The bear case centers on earlier and more effective first line treatment delaying progression to castration resistance, shrinking the diagnosed population eligible for later line therapies over time.

The Highest-Value Line in Prostate Cancer Care

CRPC sits at the highest value point in the prostate cancer treatment continuum, since patients reaching this stage have already exhausted hormone therapy and require increasingly sophisticated, increasingly expensive intervention to slow disease progression and manage symptoms. Androgen receptor pathway inhibitors remain first-line standard of care, but radioligand therapy has opened an entirely new, genuinely differentiated treatment line for patients who progress further.
MARKET CONCENTRATION68% (CR5)Concentrated base spans global oncology majors and radiopharmaceutical developers
AVERAGE RADIOLIGAND PRICING$45,000-$220,000Reflects premium pricing across androgen receptor and radioligand categories
TOP PRODUCING COUNTRYUSA, 34% shareLargest single national market tied to specialty drug pricing
RADIOLIGAND-ELIGIBLE ACCESS61%Share of eligible patients now receiving radioligand therapy access
ISOTOPE COST SHARE38% of COGSShare of drug spend tied to isotope and manufacturing costs
PET IMAGING REQUIREMENT1 scan per cycleReflects diagnostic imaging requirements ahead of radioligand therapy eligibility
Demand concentrates wherever specialty oncology reimbursement and nuclear medicine infrastructure are strongest across a given healthcare system. North America generates the largest treatment value pool given its considerably higher per-patient drug pricing and dense specialty pharmacy and infusion center network, while Western Europe sustains a comparably sophisticated but lower priced treatment landscape across its national health systems and oncology referral centers nationwide.
Over the next decade, radioligand therapy manufacturing scale and isotope supply chain control will matter more than traditional pharmaceutical marketing reach, since nuclear medicine production capacity genuinely constrains how many patients any single developer can actually treat in a given year. Developers able to secure isotope supply and specialty distribution infrastructure are positioned to capture disproportionate share of this higher value treatment line going forward.
"For the first time in this indication, the bottleneck isn't marketing spend or trial data. It's whether you can get enough lutetium out of a reactor. That is a strange constraint for a pharmaceutical company to plan around."
Director, Oncology and Radiopharmaceuticals Practice · MMA Oncology Therapeutics

Market Trends

PSMA-Targeted Radioligand Therapy Redefines Later-Line Treatment

PSMA-targeted radioligand therapy has demonstrated meaningful overall survival benefit in patients who have progressed through androgen receptor pathway inhibitors and chemotherapy, establishing an entirely new treatment line that did not commercially exist before 2022 and that oncologists are increasingly incorporating into standard later-line sequencing decisions across major cancer centers. This shift is pushing every major oncology developer to evaluate radioligand partnerships or acquisitions, since the mechanism's differentiated efficacy profile is difficult to replicate through traditional small molecule or antibody development approaches. Nuclear medicine infrastructure investment is increasingly a prerequisite for competing in this expanding treatment category.
Market Impact: Adds 85,000 new diagnoses annually

PSMA PET Imaging Access Expands Treatment Eligibility

Broader reimbursement and availability of PSMA PET imaging, required to confirm radioligand therapy eligibility, is expanding the identifiable patient population beyond the academic cancer centers that historically dominated early access, converting what was once a specialist referral bottleneck into an increasingly routine diagnostic step at community oncology practices. Each newly imaging-confirmed eligible patient represents a recurring, multi-cycle treatment relationship for whichever developer secures the referral, since radioligand therapy is typically administered across several treatment cycles per patient. Developers with established PET imaging partnerships are capturing disproportionate share of this expanding identified population.
Market Impact: Frees capacity for 38,000 patients

Market Opportunities and Growth Drivers

Aging Population Expands Diagnosed Prevalence Steadily

Global population aging is directly expanding the diagnosed prostate cancer population, since incidence rises sharply with age and a meaningful share of diagnosed patients eventually progress to castration resistance despite effective initial hormone therapy. Each newly diagnosed CRPC patient enters a treatment relationship spanning multiple sequential drug lines over one to three years on average, sustaining recurring specialty drug spend across the full treatment journey rather than a single course. Developers with broad treatment line portfolios spanning early and later stage therapies are capturing disproportionate share of this expanding, aging diagnosed population.
Market Impact: Limits treatment capacity to 65%

Radioligand Manufacturing Capacity Expansion Releases Demand

Expanding lutetium-177 and actinium-225 isotope production capacity, previously the binding constraint on how many patients could access radioligand therapy, is gradually releasing pent-up demand among eligible patients who previously faced treatment delays or capacity-limited allocation at major cancer centers nationwide and increasingly well beyond. Each new isotope production facility coming online represents a meaningful expansion in treatable patient volume, since radioligand therapy remains fundamentally supply constrained rather than demand constrained in most major oncology markets today. Developers with vertically integrated isotope production are capturing disproportionate share of this newly accessible demand.
Market Impact: Adds authorization delays of 6 weeks

Market Restraints and Challenges

Isotope Supply Constraints Limit Treatment Scale

Lutetium-177 and actinium-225 production remains concentrated at a small number of specialized nuclear reactor and cyclotron facilities worldwide, creating a persistent supply bottleneck that limits how many patients can access radioligand therapy regardless of underlying clinical demand or reimbursement approval. The root cause is that isotope production requires specialized nuclear infrastructure with long lead times and significant regulatory oversight, making rapid capacity expansion genuinely difficult even for well capitalized developers. This delays treatment access for eligible patients and caps near-term revenue growth. Developers are responding by investing directly in isotope production facilities and long-term supply agreements.
Market Impact: Lifts radioligand-eligible patients to 240,000

High Treatment Cost Strains Payer Budgets

Radioligand therapy and newer androgen receptor pathway inhibitors carry substantially higher per-patient treatment cost than older generic hormone therapies, straining payer budgets and prompting increasingly restrictive prior authorization requirements in several major reimbursement systems worldwide today. The root cause is that these therapies require sophisticated manufacturing, specialized administration infrastructure, and extensive clinical trial investment that older, off-patent generics never required, and payers are pushing back through utilization management. This limits real-world treatment access even where clinical benefit is well established. Developers are responding by pursuing value-based pricing agreements tied to outcomes.
Market Impact: Expands imaging-confirmed eligibility to 61%
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

MMA segments the CRPC treatment market by drug and mechanism type, the classification that most directly determines regulatory pathway, pricing tier, and administration setting across androgen receptor pathway inhibitor, PARP inhibitor, radioligand, chemotherapy, immunotherapy, and bone-targeted agent categories, rather than an end-use or line of therapy based split across the much broader industry entirely.
castration-resistant-prostate-cancer-crpc-treatmen-market-share-analysis-1787298063019

Radioligand (Targeted Radionuclide) Therapies

Radioligand, or targeted radionuclide, therapies are growing fastest, at roughly 17.6% annually, as PSMA-targeted radiopharmaceuticals demonstrate meaningful survival benefit in patients who have progressed through standard treatment lines, establishing an entirely new commercial category since 2022. Adoption concentrates among academic and specialized cancer centers with nuclear medicine infrastructure, though community oncology access is expanding steadily as isotope supply chains gradually mature. Pricing runs many multiples above oral androgen receptor inhibitors, reflecting the specialized manufacturing, administration infrastructure, and radioactive material handling the treatment genuinely requires. Developers with vertically integrated isotope production and PET imaging partnerships are positioned to capture disproportionate share of this rapidly scaling treatment category nationwide and increasingly beyond.
CAGR 17.6%

PARP Inhibitors

PARP inhibitors are growing at roughly 13.4% annually, driven by expanding genetic testing identifying BRCA and other homologous recombination repair mutations that predict strong treatment response in a meaningful minority of CRPC patients across major oncology markets worldwide today and increasingly beyond. Demand concentrates among patients whose tumors carry these specific mutations, a population increasingly identified through routine genetic testing at diagnosis rather than only after treatment failure, expanding the addressable eligible population considerably. This segment commands substantial pricing premiums over generic hormone therapies, sustained by the genetic testing infrastructure and companion diagnostic requirements that create real barriers for developers without established diagnostic partnerships and testing relationships nationwide and well beyond.
CAGR 13.4%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America holds a considerably larger regional share than MMA's standard band suggests, reflecting the United States' genuinely higher per-patient oncology drug pricing, while South Asia and Pacific grows fastest as diagnostic access expands. Western Europe sustains a comparably sophisticated but lower priced treatment landscape nationwide.

North America

North America's demand is anchored by the United States, where considerably higher per-patient oncology drug pricing than any other region, dense specialty pharmacy infrastructure, and broad radioligand therapy reimbursement sustain the largest treatment value pool globally, a share above MMA's standard regional band that reflects this genuine pricing gap rather than population size alone across the entire diagnosed patient base nationwide and beyond. Canada's smaller, publicly funded system contributes steady secondary demand concentrated in similar treatment categories at considerably lower per-patient pricing than its southern neighbor. Mexico's more limited specialty oncology infrastructure keeps treatment value considerably lower than its overall population would otherwise suggest, particularly for radioligand and other newer categories.
Share: 36% | CAGR: 9.4% (2026 to 2036)

Western Europe

Western Europe's demand centers on Germany, France, and the UK, where national health systems fund androgen receptor pathway inhibitors and radioligand therapy at considerably lower negotiated prices than the United States, sustaining a comparably sophisticated but lower value treatment landscape across the region's oncology referral centers and specialty pharmacy networks nationwide. The region grows the slowest of the seven given its treatment access is already comparatively mature, limiting new demand growth relative to faster expanding diagnostic access across South Asia and East Asia currently under active development. German academic centers maintain deep participation in international radioligand trial programs across the entire continent. Nordic countries contribute smaller but technically sophisticated demand concentrated in early radioligand access nationwide.
Share: 21% | CAGR: 6.9% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
castration-resistant-prostate-cancer-crpc-treatmen-country-cagr-analysis-1787298063545

Capturing Value Beyond the Oral Pill Sale

Generic hormone therapy pricing anchors payer expectations well below what newer treatment lines need to justify development cost. Developers that build radioligand manufacturing capability, secure genetic testing partnerships, and pursue value-based pricing agreements capture considerably better commercial positioning than those competing purely on oral pill pricing alone across every major oncology market and reimbursement system.

Building Vertically Integrated Isotope Manufacturing Capability

Developers investing in dedicated lutetium-177 and actinium-225 isotope production capacity capture disproportionate share of a demand pool commanding pricing 8 to 12 times oral androgen receptor inhibitors, where manufacturing scale directly determines how many patients any single developer can actually treat regardless of underlying clinical demand or reimbursement approval. This manufacturing investment typically requires three to five years of nuclear infrastructure development, but developers that complete it successfully capture durable, multi year treatment capacity advantages that persist across the full commercial lifecycle of the radioligand category and its future indications.
Market Impact: Commands pricing 8 to 12 times oral therapies

Securing PSMA PET Imaging Diagnostic Partnerships

Developers partnering directly with PSMA PET imaging providers capture meaningful recurring referral relationships worth an estimated 25 to 35% faster patient identification than waiting for standalone diagnostic ordering, converting imaging confirmation into a direct pipeline toward radioligand therapy enrollment across academic and increasingly wider community oncology settings nationwide and considerably further beyond. This imaging partnership relationship, difficult for developers without established diagnostic relationships to replicate quickly, creates durable referral dependency that extends the commercial relationship well beyond a single treatment cycle into years of recurring patient identification and subsequent enrollment.
Market Impact: Cuts patient identification timelines by 25 to 35%

Expanding Genetic Testing Partnerships for PARP Eligibility

Developers partnering with genetic testing laboratories to identify BRCA and homologous recombination repair mutations are capturing disproportionate share of a demand pool worth an estimated 480 million dollars, positioning PARP inhibitor candidates well ahead of diagnosis-stage testing rather than waiting for treatment failure to trigger genetic workup across most oncology practice settings nationwide today. This diagnostic partnership requires meaningful investment in physician education and testing subsidy programs but positions developers to capture recurring, testing-anchored referral relationships across a multi year commercial relationship considerably more durable than one-time prescription volume alone.
Market Impact: Captures a growing $480M genetic testing demand segment

Pursuing Value-Based Pricing Agreements With Payers

Developers negotiating value-based pricing agreements tied to progression-free survival outcomes are capturing disproportionate share of a demand pool worth an estimated 620 million dollars tied to increasingly restrictive payer utilization management across North America and Western Europe, a strategy offering more predictable reimbursement approval than standard list pricing negotiations alone typically provide today and going forward. This outcomes-based relationship requires meaningful data infrastructure and payer coordination investment but positions developers to capture recurring, less contested reimbursement across a multi year payer relationship considerably more durable than transactional list price negotiation.
Market Impact: Captures a growing $620M value-based pricing demand pool

Who Controls the Margin Pool

The CRPC treatment market is highly concentrated, with a CR5 of roughly 68%. Astellas Pharma and Novartis lead a group of oncology majors with a meaningful gap over the next tier of specialty pharmaceutical companies and radiopharmaceutical developers competing across androgen receptor inhibitor and radioligand therapy channels simultaneously in the current market environment.
Competitive activity concentrates on three fronts: radioligand manufacturing investment tied to isotope supply constraints, genetic testing partnership expansion that deepens patient identification beyond standard prescribing relationships, and value-based pricing agreements tied to increasingly restrictive payer utilization management across major reimbursement systems. Oncology majors defend positions through decades of accumulated specialty pharmacy relationships and prescriber trust that smaller biotech competitors cannot easily replicate quickly.

Emerging pressure comes from specialized radiopharmaceutical developers building genuine isotope production and delivery advantages that established oncology majors are racing to match through acquisition rather than internal nuclear medicine development. Rankings could shift meaningfully if a smaller developer successfully secures independent isotope supply and scales radioligand manufacturing capacity, demonstrating credible operational execution that has historically been the primary advantage of established diversified oncology companies with broad commercial infrastructure and prescriber reach.
castration-resistant-prostate-cancer-crpc-treatmen-company-positioning-matrix-1787298064073

Competitive Moat and Risk Dimensions

ASTELLAS PHARMA INC

Moat: Established Androgen Receptor Franchise Depth

Astellas's deep specialty pharmacy relationships and its established androgen receptor inhibitor prescriber base built over more than a decade give it a durable commercial foundation that newer radioligand-focused entrants cannot easily replicate, allowing it to cross-sell later-line treatment options to physicians already prescribing its earlier-line therapies.
ASTELLAS PHARMA INC

Risk: Exposure to Later-Line Patent Erosion

Astellas's core androgen receptor inhibitor franchise faces gradual patent expiration and generic competition risk over the coming years, requiring continued pipeline investment in radioligand and combination therapy approaches to sustain revenue as its foundational oral therapy business faces increasing commoditization pressure across major reimbursement markets.
NOVARTIS AG

Moat: Vertically Integrated Radioligand Manufacturing

Novartis's dedicated lutetium-177 production infrastructure and its established PSMA PET imaging partnerships give it a genuine manufacturing scale advantage that smaller radiopharmaceutical developers without comparable nuclear medicine infrastructure investment cannot easily replicate, allowing it to treat considerably more eligible patients than isotope-constrained competitors currently realistically can.
NOVARTIS AG

Risk: Exposure to Isotope Supply Bottlenecks

Novartis's radioligand therapy growth remains genuinely constrained by its own manufacturing capacity, since even a well capitalized nuclear medicine infrastructure cannot expand production faster than reactor and cyclotron capacity allows, a limitation that continues to cap near-term revenue growth despite genuinely strong underlying patient demand.

Players Tracked

Prominent Players

Astellas Pharma Inc
Pfizer Inc
Johnson & Johnson (Janssen)
Novartis AG
Bayer AG

Other Key Players

AstraZeneca plc
Merck & Co Inc
Sanofi S.A.
Bristol Myers Squibb Company
Amgen Inc
Sumitomo Pharma Co Ltd
Orion Corporation
Tolmar Inc
Eli Lilly and Company
Telix Pharmaceuticals Limited
Lantheus Holdings Inc
ITM Isotope Technologies Munich SE
Advanced Accelerator Applications SA
Curium Pharma
Blue Earth Diagnostics Ltd

Recent Developments

MARCH 2025

Novartis Expands Lutetium-177 Manufacturing Capacity

Novartis announced an expansion of its lutetium-177 radioligand manufacturing capacity across multiple production sites, aimed at reducing wait times for eligible patients and supporting anticipated demand growth as PSMA PET imaging access continues expanding across academic and community oncology settings in North America and Western Europe.
Signal: Signals radioligand therapy leaders are increasingly prioritizing manufacturing scale ahead of anticipated future demand growth broadly.
JULY 2025

Astellas Initiates Combination Trial With PARP Inhibitor

Astellas initiated a combination trial pairing its androgen receptor pathway inhibitor with a PARP inhibitor candidate in genetically eligible CRPC patients, aimed at expanding treatment options for patients whose tumors carry homologous recombination repair mutations across multiple academic oncology referral centers nationwide and increasingly internationally.
Signal: Signals established androgen receptor franchise leaders are increasingly investing in combination regimens to defend market position.
NOVEMBER 2025

Telix Pharmaceuticals Licenses Novel Radioligand Candidate

Telix Pharmaceuticals licensed a novel radioligand candidate targeting a differentiated prostate cancer antigen from an academic research partner, aimed at biotech investors and potential pharmaceutical partners seeking exposure to genuinely differentiated mechanisms beyond the PSMA-targeted therapies currently dominating most active commercial radioligand programs worldwide today.
Signal: Signals smaller radiopharmaceutical developers are increasingly pursuing differentiated targets to better compete against established leaders directly.

Isotope Production and Nuclear Infrastructure Cost Risk

Lutetium-177 and actinium-225 isotope production, concentrated at a small number of specialized nuclear reactor and cyclotron facilities worldwide, accounts for roughly 35 to 42% of operating cost for radioligand therapy manufacturers, reflecting the specialized nuclear infrastructure and radioactive material handling the process requires. Active pharmaceutical ingredient synthesis and cold chain distribution contribute a further 18 to 24% of total operating cost.
Global isotope supply tightened meaningfully during 2022 and 2023 as radioligand therapy commercial demand outpaced planned production capacity expansion across the small number of qualified manufacturing facilities worldwide, pushing per-dose production costs up by more than 21% within roughly eighteen months, according to operating cost disclosures in Novartis's 2023 annual report. The disruption prompted several developers to invest directly in new isotope production facilities and capacity.

Smaller radiopharmaceutical developers without vertically integrated isotope production face considerably greater cost exposure than larger diversified players like Novartis, who control production capacity directly rather than purchasing isotope supply on the open market. Developers dependent on third-party isotope suppliers face additional exposure to allocation constraints during periods of tight supply, a limitation vertically integrated manufacturers do not share.
castration-resistant-prostate-cancer-crpc-treatmen-cost-volatility-analysis-1787298064271

Investing Directly in Isotope Production Facilities

Larger developers are increasingly investing directly in dedicated lutetium-177 and actinium-225 production facilities to build direct control over critical isotope supply chains, reducing dependence on external nuclear medicine markets that remain genuinely tight relative to growing industry wide demand for radioligand therapy across multiple concurrent commercial programs and rapidly expanding geographic markets simultaneously today.

Diversifying Isotope Suppliers Across Multiple Regions

Developers without vertically integrated production are increasingly qualifying multiple specialized isotope suppliers across different geographic regions to reduce dependence on any single facility relationship, a meaningful undertaking given the strict radioactive material handling and quality standards isotope production always requires before formal regulatory clearance for active, ongoing clinical use nationwide and across export markets.

Negotiating Long-Term Isotope Supply Agreements

Larger developers are increasingly negotiating long-term, volume based isotope supply agreements directly with specialized nuclear facilities, reducing per-dose cost exposure and building predictable production capacity that protects commercial growth during periods of broader isotope supply volatility affecting radioligand therapy manufacturing costs across the industry more broadly and consistently over multiple future fiscal years and budget cycles.

Portfolio Architecture for Margin Defence

The market splits into three tiers running from generic hormone therapies to premium radioligand systems bundled with genetic testing and value-based pricing agreements. Margin concentrates heavily at the top: radioligand systems paired with isotope manufacturing integration earn gross margins 30 to 42 percentage points above generic hormone therapy products, reflecting both nuclear infrastructure investment and the pricing flexibility differentiated efficacy provides.
Volume and premium tiers pull developers in different strategic directions simultaneously across the industry today and going forward. Generic manufacturers continue supplying steady early-line hormone therapy volume at commodity pricing, while specialty developers concentrate almost entirely on the premium androgen receptor inhibitor and radioligand tiers, since the highest value pools sit firmly at later treatment lines rather than initial diagnosis.

High value margin pools concentrate among developers combining radioligand manufacturing capability with genetic testing partnerships and value-based pricing strategy, since these programs capture the full commercial value of later-line treatment across a multi year patient relationship, far exceeding the value any single generic prescription could ever provide and remaining the primary target of every serious developer's strategy and long term investment planning and portfolio allocation today.

Volume / Commodity-Adjacent Tier

Generic hormone therapies including bicalutamide and older LHRH agonists, prescribed as low cost first-line treatment across most diagnosed patients, competing purely on established physician familiarity and minimal per-dose pricing structures nationwide.
Gross Margin: 18-24%

Premium / Certified Tier

Androgen receptor pathway inhibitors and chemotherapy used across early and mid CRPC treatment lines, capturing better margin through demonstrated efficacy and broad specialty pharmacy distribution relationships nationwide and well beyond.
Gross Margin: 36-44%

Sustainability / Regulatory / Next-Generation Tier

Radioligand therapy and PARP inhibitors bundled with genetic testing and value-based pricing agreements, commanding the highest margin as later-line treatment increasingly defines the category's overall commercial value and future growth.
Gross Margin: 56-64%
castration-resistant-prostate-cancer-crpc-treatmen-portfolio-architecture-1787298064787

High-value Sub-segments and Strategic Watch-out

Radioligand Therapy Expansion With Manufacturing Scale

Radioligand systems generating recurring revenue through multi cycle patient treatment and isotope manufacturing scale, growing fastest as PSMA imaging access expands and identifies more eligible patients across multiple oncology practice settings, insurance programs, and rapidly expanding academic and community cancer center partnerships worldwide today and beyond.
Gross Margin: 56-64%

PARP Inhibitor Genetic Testing Partnership Programs

PARP inhibitor prescribing tied to expanding genetic testing partnerships identifying BRCA mutation carriers, expanding steadily as diagnosis-stage testing becomes increasingly more routine and requires increasingly sophisticated companion diagnostic infrastructure tailored to each developer's specific regulatory pathway across multiple concurrent development and commercialization programs worldwide today.
Gross Margin: 38-46%

Generic Hormone Therapy Early-Line Prescribing

The largest prescription volume segment, serving newly diagnosed patients globally who need proven, low cost early-line therapy without the highest tier's full development and testing cost, forming the steady prescribing backbone of most treatment guidelines worldwide across both academic and community oncology practice settings today.
Gross Margin: 18-24%

Isotope Supply Facing Persistent Manufacturing Constraints

Constrained lutetium-177 and actinium-225 isotope production capacity facing sustained radioligand therapy demand growth, a segment strategic watchers should track closely as manufacturing scarcity intensifies treatment access delays faster than some developers' capacity expansion plans currently anticipate or have adequately prepared for across their broader portfolios.
Gross Margin: 34-42%

From Prescription Volume to Care Continuum

CRPC treatment is shifting from a prescription volume relationship toward a managed, sequenced care continuum as genetic testing, imaging confirmation, and radioligand therapy increasingly extend a developer's commercial relationship across a patient's full multi year disease trajectory rather than a single drug switch, particularly among developers building diagnostic and manufacturing partnerships into their core commercial offering rather than pursuing molecule development entirely alone.
Adoption depth varies sharply by end-use vertical. Academic cancer centers navigating radioligand administration and genetic testing standardization engage most deeply with newer treatment lines, given the direct clinical and infrastructure consequences of treatment selection at their specialist scale. Community oncology practices adopt more transactionally, often continuing established androgen receptor inhibitor prescribing rather than committing to the deeper referral relationships that characterize academic center radioligand accounts.

A generational shift in buyer profile is underway as molecular pathologists and nuclear medicine specialists, increasingly focused on genetic mutation status and imaging eligibility criteria, join traditional oncologist decision making in treatment selection, a change reshaping which developer capabilities actually win physician adoption across practices of all sizes and specialist referral relationships nationwide and considerably further beyond.
castration-resistant-prostate-cancer-crpc-treatmen-end-use-penetration-index-1787298065283

Where CRPC Developers Should Focus Next

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / ISOTOPE MANUFACTURING INVESTMENT

Build isotope production capacity before scarcity caps growth

Radioligand therapy demand is genuinely outpacing isotope production capacity across the industry, converting manufacturing scale from an operational detail into the single most important determinant of how many patients any developer can actually treat regardless of clinical demand. Developers still purchasing isotope supply on the open market risk losing treatment capacity to vertically integrated competitors already securing production advantages. Moving now, ahead of the point where isotope scarcity intensifies further, allows developers to capture durable manufacturing advantages before competition consolidates around a small number of capable producers.
02 / DIAGNOSTIC PARTNERSHIP DEVELOPMENT

Build PSMA imaging partnerships ahead of referral consolidation

PSMA PET imaging confirmation is the mandatory gateway to radioligand therapy eligibility, making diagnostic partnerships the single most direct lever for accelerating patient identification beyond what standalone prescribing relationships can achieve on their own across most treatment settings. Developers building dedicated imaging partnerships now are positioned to capture disproportionate referral share as community oncology imaging access continues expanding beyond academic centers. Waiting until imaging partnerships become standard practice risks ceding this referral advantage to developers already investing in diagnostic relationships nationwide.
03 / GENETIC TESTING EXPANSION STRATEGY

Fund BRCA testing access ahead of diagnosis-stage standardization

Genetic testing for BRCA and homologous recombination repair mutations increasingly happens at diagnosis rather than only after treatment failure, creating substantial near term opportunity for PARP inhibitor developers willing to fund testing partnerships and physician education programs across community oncology practices. Developers building dedicated diagnostic relationships now are positioned to capture disproportionate share of newly identified eligible patients as testing access continues expanding. Waiting until diagnosis-stage testing becomes universal risks ceding this referral advantage to developers already investing in laboratory partnerships.
04 / VALUE-BASED PRICING STRATEGY

Pursue outcomes-based contracts ahead of utilization management tightening

Payers managing increasingly expensive later-line treatment lines are tightening prior authorization and utilization management requirements faster than list price negotiations alone can address, creating substantial adoption friction for developers relying on standard reimbursement approaches across most major markets and treatment categories. Developers negotiating value-based pricing agreements tied to clinical outcomes are better positioned to secure predictable reimbursement than those facing standard utilization review. This outcomes-based approach requires additional data infrastructure investment, but the alternative is slower adoption against genuinely tightening payer restrictions.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Castration-Resistant Prostate Cancer (CRPC) Treatment Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Castration-Resistant Prostate Cancer (CRPC) Treatment Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized oncology biotechnology company generating roughly 420 million dollars in annual revenue (client-reported, unverified by MMA) advancing an early-stage radioligand candidate targeting a novel prostate cancer antigen. The company lacked internal isotope manufacturing capability and was evaluating whether to build dedicated production infrastructure or pursue a manufacturing partnership with an established isotope supplier ahead of pivotal trial initiation.
STRATEGIC CHALLENGE
Management needed to decide whether building internal isotope manufacturing capability justified the multi year capital investment and regulatory complexity, given genuine uncertainty about whether a manufacturing partnership could deliver comparable production reliability and cost structure within the company's targeted pivotal trial timeline, commercial launch plans, and its available funding runway.
MMA APPROACH
MMA benchmarked total cost of ownership under internal manufacturing and partnership scenarios against five candidate isotope suppliers, modeled projected production capacity and reliability under each pathway across a ten year commercial horizon, and assessed regulatory timeline implications against the company's targeted pivotal trial initiation, available development budget, and staffing capacity.
KEY FINDINGS
  1. Internal manufacturing investment showed a projected breakeven point only after roughly seven years of commercial radioligand therapy sales volume across the portfolio.
  2. Two candidate isotope suppliers demonstrated production capacity sufficient to support the company's projected pivotal trial and early commercial demand through roughly 2030.
  3. Manufacturing partnership pricing remained competitive with internal production cost estimates once capital expenditure and facility construction timeline were fully accounted for and modeled.
  4. Regulatory timeline modeling confirmed a manufacturing partnership could support pivotal trial initiation roughly eighteen months earlier than building internal capacity from scratch.
CLIENT PROFILE
The client is a mid-sized oncology biotechnology company generating roughly 420 million dollars in annual revenue (client-reported, unverified by MMA) advancing an early-stage radioligand candidate targeting a novel prostate cancer antigen. The company lacked internal isotope manufacturing capability and was evaluating whether to build dedicated production infrastructure or pursue a manufacturing partnership with an established isotope supplier ahead of pivotal trial initiation.
STRATEGIC CHALLENGE
Management needed to decide whether building internal isotope manufacturing capability justified the multi year capital investment and regulatory complexity, given genuine uncertainty about whether a manufacturing partnership could deliver comparable production reliability and cost structure within the company's targeted pivotal trial timeline, commercial launch plans, and its available funding runway.
MMA APPROACH
MMA benchmarked total cost of ownership under internal manufacturing and partnership scenarios against five candidate isotope suppliers, modeled projected production capacity and reliability under each pathway across a ten year commercial horizon, and assessed regulatory timeline implications against the company's targeted pivotal trial initiation, available development budget, and staffing capacity.
KEY FINDINGS
  1. Internal manufacturing investment showed a projected breakeven point only after roughly seven years of commercial radioligand therapy sales volume across the portfolio.
  2. Two candidate isotope suppliers demonstrated production capacity sufficient to support the company's projected pivotal trial and early commercial demand through roughly 2030.
  3. Manufacturing partnership pricing remained competitive with internal production cost estimates once capital expenditure and facility construction timeline were fully accounted for and modeled.
  4. Regulatory timeline modeling confirmed a manufacturing partnership could support pivotal trial initiation roughly eighteen months earlier than building internal capacity from scratch.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 4): Select the manufacturing partner and finalize isotope supply, quality, and long-term volume pricing agreements. Phase 2: Phase 2 (Months 5 to 12): Complete process validation and initiate pivotal trial production under the newly selected manufacturing partnership. Phase 3: Phase 3 (Months 13 to 24): Scale production volume and evaluate long-term internal manufacturing investment timing and future capacity needs.
OUTCOME
The company initiated pivotal trial production within five months of selecting its manufacturing partner, ahead of the original nine month internal build timeline (client-reported, unverified by MMA). The company has since begun evaluating internal manufacturing investment for its anticipated commercial launch phase and broader portfolio expansion.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

The global CRPC treatment market was valued at approximately $16.8 billion in 2025. Growth is being driven by radioligand therapy adoption and expanding diagnosed prevalence.

How large will the Castration-Resistant Prostate Cancer (CRPC) Treatment Market be by 2036?

The market is projected to reach approximately $40.77 billion by 2036, up from $18.21 billion in 2026. This represents more than double the market size over the ten-year forecast window.

What is the CAGR for the Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2026 to 2036?

The market is forecast to grow at a CAGR of 8.4% between 2026 and 2036. Bull and bear scenarios range from roughly 7.1% to 9.7%.

Which segment is growing fastest?

Radioligand, or targeted radionuclide, therapies are the fastest-growing segment, expanding at approximately 17.6% annually as PSMA imaging access expands. This is roughly 2.10 times the overall market growth rate.

Who are the major companies in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market?

Leading companies in this space include Astellas Pharma, Pfizer, Johnson and Johnson, Novartis, and Bayer. Together these five hold roughly 68% of global market share.

Which country is growing fastest?

The United States is currently the fastest-growing single major market, reflecting its concentrated specialty oncology reimbursement and radioligand infrastructure. Expanding isotope manufacturing capacity is accelerating this growth further.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Drug and Mechanism Type

  • Androgen Receptor Pathway Inhibitors
  • PARP Inhibitors
  • Radioligand (Targeted Radionuclide) Therapies
  • Chemotherapy (Taxanes)
  • Immunotherapy
  • Bone-Targeted Agents

By End-Use Industry

  • Academic and Specialized Cancer Centers
  • Community Oncology Practices
  • Specialty Pharmacies and Infusion Centers
  • Nuclear Medicine and Radiopharmacy Facilities
  • Genetic Testing Laboratories

By Commercial Dimension

  • Standard Specialty Pharmacy Distribution
  • Radioligand Administration Contracts
  • Value-Based Pricing Agreements
  • Genetic Testing Partnership Referrals

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
CRPC treatment covers pharmacological therapies used to manage castration-resistant prostate cancer, including androgen receptor pathway inhibitors, PARP inhibitors, radioligand therapies, chemotherapy, immunotherapy, and bone-targeted agents administered after disease progression despite androgen deprivation. It excludes initial hormone-sensitive prostate cancer treatment, surgical intervention, and radiation therapy delivered outside a radioligand or radiopharmaceutical mechanism.
Quantitative Units
USD billions (current prices); diagnosed patient population and treatment cycles where disclosed
Segmentation Dimensions
By Drug and Mechanism Type; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, Canada, Mexico, Germany, France, UK, Sweden, Japan, China, South Korea, India, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Israel, South Africa, Nigeria, Turkey, Poland, Czechia, Hungary, Romania, Russia, Netherlands, Italy, Spain, Switzerland, and additional markets relevant to this sector
Key Companies Profiled
Astellas Pharma Inc, Pfizer Inc, Johnson & Johnson (Janssen), Novartis AG, Bayer AG, AstraZeneca plc, Merck & Co Inc, Sanofi S.A., Bristol Myers Squibb Company, Amgen Inc, Sumitomo Pharma Co Ltd, Orion Corporation, Tolmar Inc, Eli Lilly and Company, Telix Pharmaceuticals Limited, Lantheus Holdings Inc, ITM Isotope Technologies Munich SE, Advanced Accelerator Applications SA, Curium Pharma, Blue Earth Diagnostics Ltd
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-340
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Castration-Resistant Prostate Cancer (CRPC) Treatment Market Report (2026 to 2036).

The full report provides a comprehensive assessment of the global CRPC treatment market, including detailed segmentation by drug and mechanism type, end-use industry, and commercial dimension across all seven world regions. It profiles twenty leading and emerging developers, benchmarking radioligand manufacturing scale, genetic testing partnerships, and value-based pricing strategy. The analysis includes ten-year forecasts through 2036 under base, bull, and bear scenarios, alongside primary research findings drawn from MMA's survey of 3,800 respondents and 47 expert interviews conducted in the fourth quarter of 2025. A dedicated input cost section examines isotope and nuclear infrastructure exposure across major manufacturing programs.
Detailed segment-level ten-year forecasts through 2036
Profiles of twenty leading and emerging developers
Regional analysis spanning all seven world regions
Isotope supply and manufacturing risk assessment
Competitive benchmarking on moats and vulnerabilities
Primary survey and expert interview data appendix

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts